SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Ondas, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Inc.

Ondas Inc

Ondas Inc. is trending as investors react to a significant earnings beat and raised full-year revenue guidance, sparking intense debate over whether the stock's growth potential justifies its complex capital structure. The community is actively weighing the company's surging backlog and defense partnerships against persistent concerns regarding dilution and the influence of market makers on share price volatility.

Intuitive Machines, Inc. is a space exploration, infrastructure, and services company, which engages in contributing to the establishment of cislunar infrastructure and helping to develop cislunar and deep space commerce. It offers space products and services. The company was founded by Stephen J. Altemus, Kam Ghaffarian, and Timothy P. Crain in 2013 and is headquartered in Houston, TX.

Intuitive Machines Inc - Ordinary Shares - Class A

Intuitive Machines Inc

Intuitive Machines is surging as investors cheer its record revenue, positive EBITDA, and strategic acquisition of Goonhilly Earth Station. The stock is a focal point of intense community debate, with bulls citing multi-year growth potential and upcoming contract catalysts, while others monitor the volatility surrounding its high-volume price swings.

Robinhood Ventures Fund I invest in companies located in the United States. The fund focuses on a broad range of sectors and industries. It provides financing for early stage transactions.

Robinhood Ventures Fund I - Common shares of beneficial interest

Robinhood Ventures Fund (RVI) is seeing intense volatility and massive volume as retail traders speculate on its private AI-heavy portfolio, specifically its exposure to high-growth firms like Databricks and OpenAI. The community is sharply divided, with bulls viewing the fund as a rare, accessible play on pre-IPO tech giants while skeptics warn that the current market price represents an unsustainable premium to the fund's underlying net asset value.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

CorMedix is seeing strong trading activity driven by a triple-digit revenue surge and increased guidance for the fiscal year, with investors debating the potential for long-term growth and the impact of upcoming reimbursement changes. The community is actively discussing the company's path to profitability, the commercial outlook for its DefenCath and Rezzayo products, and speculation regarding potential strategic moves or acquisition interest from larger dialysis providers.

Ford Motor Co. engages in the manufacture, distribution, and sale of automobiles. It operates through the following segments: Ford Blue, Ford Model E, Ford Pro, Ford Credit, and Corporate Other. The Ford Blue, Ford Model E, and Ford Pro segment includes the sale of Ford and Lincoln vehicles, service parts, and accessories, together with the associated costs to develop, manufacture, distribute, and service the vehicles, parts, and accessories. The Ford Credit segment consists of the Ford Credit business on a consolidated basis, which is primarily vehicle-related financing and leasing activities. The Corporate Other segment refers to corporate governance expenses, past service pension and OPEB income and expense, interest income and gains and losses from cash, cash equivalents, and marketable securities, and foreign exchange derivatives gains, and losses associated with intercompany lending. The company was founded by Henry Ford on June 16, 1903 and is headquartered in Dearborn, MI.

Ford Motor Co.

Ford Motor Co

Ford is seeing heightened investor activity and volatility following the launch of a new energy subsidiary focused on battery storage systems for data centers and industrial infrastructure. The community is actively debating the company's strategic pivot toward AI-linked energy demands, with options traders heavily positioning for long-term price movement despite mixed sentiment regarding executive leadership and ongoing recall challenges.

Klarna Group Plc is a global digital bank and flexible payments provider. It operates through an AI-powered payments and commerce network that empowers people to pay smarter, with a mission to be available everywhere, for everything. The company was founded by Gustav Erik Niklas Adalberth, Karl Anders Victor Jacobsson, and Sebastian Marcin Siemiatkowski in 2005 and is headquartered in London, the United Kingdom.

Klarna Group plc

Klarna is facing significant market volatility as investors weigh strong growth and a series of strategic partnerships against bearish sentiment driven by high short interest and macroeconomic headwinds. The community is closely watching upcoming legal catalysts, including a high-stakes antitrust damages proceeding involving PriceRunner, which many believe is a pivotal factor for the stock's future performance.

Nokia Oyj engages in the provision of network infrastructure, technology, and software services. It operates through the following segments: Mobile Networks, Network Infrastructure, Cloud and Network Services, and Nokia Technologies. The Mobile Networks segment offers technologies for Radio Access Networks (RAN) as well as Microwave Radio Links (MWR) for transport networks. The Network Infrastructure serves communication service providers, enterprises, webscales and public sector customers. The Cloud and Network Services segment builds around software and the cloud and is focused on driving leadership in cloud-native software and as-a-service delivery models, as demand for critical networks accelerates; and with strong market positions in communications software, private wireless networks, and cognitive (or intelligent) services. The Nokia Technologies segment, building on decades of innovation and R&D leadership in technologies used in virtually all mobile devices used today, is expanding the Nokia patent licensing business, reintroducing the Nokia brand to smartphones through brand licensing, and establishing a technology licensing business. The company was founded by Fredrik Idestam in 1865 and is headquartered in Espoo, Finland.

Nokia Corp - ADR

Nokia Corp

Nokia is trending as investors rally around the company's aggressive expansion into agentic AI for broadband networks and its integration into the AI-native 6G and cloud infrastructure ecosystem. The community is heavily focused on intense call option activity and potential upcoming milestones, viewing the stock as an undervalued play transitioning into a critical component of the AI supply chain.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics is experiencing significant momentum as investors position themselves ahead of the upcoming AUA Annual Meeting, where the company is slated to present practice-changing extended follow-up data for its prostate cancer therapy. The community is actively discussing the stock's potential for a major re-rating, with widespread speculation regarding a potential buyout and excitement over the firm's strengthened balance sheet and upcoming BLA submission.

Canadian Solar, Inc. engages in the manufacture of solar photovoltaic modules, provision of solar energy and battery storage solutions, and development of utility-scale solar and battery storage products. It operates through the CSI Solar and Global Energy segments. The CSI Solar segment designs, develops, and manufactures solar ingots, wafers, cells, modules, and other solar power and battery storage products. The Global Energy segment includes solar and battery storage project development and sale, asset management services for operational projects, sale of electricity, and investment in retained assets. The company was founded by Shawn Qu in October 2001 and is headquartered in Kitchener, Canada.

Canadian Solar Inc

Canadian Solar is experiencing significant volatility as investors weigh the company's aggressive U.S. manufacturing expansion and promising storage backlog against concerns over debt levels and soft near-term guidance. The community is actively debating the potential for an eventual share price re-rating driven by upcoming IRA manufacturing tax credits, while short sellers remain highly active amid persistent questions regarding executive leadership, balance sheet health, and the timing of asset monetization.

Cisco Systems, Inc. engages in the design, manufacture, and sale of Internet Protocol-based networking products and services related to the communications and information technology industry. The firm operates through the following geographical segments: the Americas, EMEA, and APJC. Its products include the following categories: Secure, Agile Networks, Internet for the Future, Collaboration, End-to-End Security, Optimized Application Experiences, and Other Products. The company was founded by Sandra Lerner and Leonard Bosack in 1984 and is headquartered in San Jose, CA.

Cisco Systems, Inc.

Cisco is surging as the market re-rates the company as a critical AI infrastructure play following better-than-expected earnings and a massive boost in hyperscaler AI orders. Investors are focused on its strategic shift toward networking, silicon, and data center connectivity, with many noting its newfound momentum as it breaks toward record highs.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>So far this week, SLS has gained nearly 30%, on track for its best week since the week ended Jan 2, if gains hold.</li><li>SELLAS is advancing two key programs in AML.</li><li>According to data from Koyfin, the two analysts covering Sellas rate it ‘Buy’ or higher.</li></ul>Shares of Sellas Life Sciences Group Inc (SLS) closed up 25% on Wednesday, a day after the company said that its pivotal late-stage trial of galinpepimut-S (GPS) in acute myeloid leukemia (AML) is now just two events away from triggering a topline data readout.As of May 11, 2026, 78 deaths had occurred in the study, called REGAL, the company said. The prespecified 80th event will trigger analysis and disclosure of results, the company said. SELLAS remains blinded to the data as the study is being conducted by a contract research organization.So far this week, SLS has gained nearly 30%, on track for its best week since the week ended Jan 2, if gains hold. To December-end, the company reported that 72 out of the prespecified 80 patient deaths required to trigger the final analysis had occurred as of Dec. 26, 2025, sparking a rally.According to data from Koyfin, the two analysts covering Sellas rate it ‘Buy’ or higher. The 12-month average price target on the stock is $10, representing a potential upside of about 53% from the stock’s closing price on Wednesday.<h2 class="st-heading-2">How Did Sellas Retail Traders React?</h2>On Stocktwits, retail sentiment stayed within the ‘bullish’ territory over the past 24 hours, while message volume increased from ‘normal’ to ‘high’ levels. According to platform data, retail chatter around SLS jumped nearly 500% over the past 24 hours and by about 400% over the past seven days.A Stocktwits user opined that the shares of the company will drop once the data is announced.<stembedurl>https://www.stocktwits.com/BIG_BEAR_/message/653285528</stembedurl>Another user opined that the imminent trial results would be “transformational.”<stembedurl>https://www.stocktwits.com/Evie47/message/653284589</stembedurl>A third user highlighted that Sellas has not one but two “blockbuster assets.” “...in no dimension, this dimension or alternative dimension should SLS be a single-digit stock &amp;/or at this valuation this late into development,” they wrote.<stembedurl>https://www.stocktwits.com/Mr_Anderson007/message/653248347</stembedurl>“...we believe that the upcoming results, triggered by reaching the pre-specified 80th event, will be an important milestone for the Company,” Sellas CEO Angelos Stergiou said about the GPS trial outcome.SELLAS is advancing two key programs in AML. In addition to the REGAL trial, the company has begun dosing patients in an 80-patient mid-stage trial of its experimental drug SLS009 in newly diagnosed, first-line AML patients.<a href="https://stocktwits.com/symbol/SLS">SLS stock </a>has gained over 350% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/nvidia-stock-draws-attention-as-culper-research-takes-short-position-over-china-ties/cZXLrSBReKF">Nvidia Stock Draws Attention As Culper Research Takes Short Position Over China Ties</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the SELLAS Life Sciences Group logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

SLS On Track For Best Week In Over 4 Months: Retail Divided Between Stock Drop Or Multibagger Status Amid Upcoming Cancer Trial Data

As of May 11, 2026, 78 deaths had occurred in the study, called REGAL, the company said on Tuesday. 

Equity

As of May 11, 2026, 78 deaths had occurred in the study, called REGAL, the company said on Tuesday. 


<ul class="summary-bullets"><li>SELLAS is advancing two key programs in AML.</li><li>For Q1, SLS reported a higher net loss as it prepares for a potential application filing to the U.S. Food and Drug Administration for GPS.&nbsp;</li><li>The data readout from the GPS trial will be triggered by a pre-specified event.&nbsp; &nbsp;</li></ul>Shares of SELLAS Life Sciences Group (SLS) jumped more than 20% in after-hours trading Monday following the company’s announcement that its pivotal late-stage trial of galinpepimut-S (GPS) in acute myeloid leukemia (AML) is now just two events away from triggering topline data readout.As of May 11, 2026, 78 deaths had occurred in the study, called REGAL, the company said. The prespecified 80th event will trigger analysis and disclosure of results, the company said. SELLAS remains blinded to the data as the study is being conducted by a contract research organization.In December, the company reported that 72 out of the prespecified 80 patient deaths required to trigger the final analysis had occurred as of Dec. 26, 2025.“...we believe that the upcoming results, triggered by reaching the pre-specified 80th event, will be an important milestone for the Company,” Sellas CEO Angelos Stergiou said.<h2 class="st-heading-2">Pipeline Highlights</h2>SELLAS is advancing two key programs in AML. In addition to the REGAL trial, the company has begun dosing patients in an 80-patient mid-stage trial of its experimental drug SLS009 in newly diagnosed, first-line AML patients, including high-risk subsets. Topline data from this study are expected in the fourth quarter of 2026.Stergiou said that Sellas is “entering an exciting time with multiple, high-value potential catalysts that could transform the AML treatment landscape.”<h2 class="st-heading-2">Financial Results and Guidance</h2>As of March 31, 2026, SELLAS had $107.1 million in cash and cash equivalents. The company has since received an additional $7.5 million from the exercise of warrants in the second quarter, extending its cash runway.The company has also established a new at-the-market (ATM) equity facility that gives it the ability to raise up to $150 million over time, though no shares have been sold under the program to date.For the first quarter ended March 31, 2026, SELLAS reported a net loss of $8.4 million, compared with a net loss of $5.8 million in the year-ago period. The increase was driven primarily by higher research and development spending as the company prepares for a potential application filing to the U.S. Food and Drug Administration for GPS following the REGAL readout.<h2 class="st-heading-2">How Did SLS Retail Traders React?</h2>On Stocktwits, retail sentiment around SLS rose from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume increased from ‘normal’ to ‘high’ levels.A Stocktwits user voiced hopes for further rally.<stembedurl>https://www.stocktwits.com/MoMoney80/message/653149990</stembedurl>Another expressed anticipation for the REGAL trial data, noting that it is “nearly here.”<stembedurl>https://www.stocktwits.com/Leotto/message/653149831</stembedurl>A third user expressed optimism for the data triggering an FDA approval, causing a 10x jump in share price.<stembedurl>https://www.stocktwits.com/55X_ROI_Q1_2026/message/653149438</stembedurl>According to data from Koyfin, the two analysts covering Sellas rate it ‘Buy’ or higher. The 12-month average price target on the stock is $10, representing a potential upside of over 90% from the stock’s closing price on Tuesday.<a href="https://stocktwits.com/symbol/SLS">SLS stock</a> has more than tripled over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-invests-250-million-in-cell-manufacturing-at-giga-berlin/cZXXYivRe0G">Tesla Invests $250M In Cell Manufacturing At Giga Berlin As It Eyes Model Y Production Ramp In H2</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

SLS Stock Pops Big After Hours On Imminent Leukemia Trial Data Readout Optimism

Sellas investors are now awaiting data readout from the firm’s late-stage trial of galinpepimut-S or GPS in acute myeloid leukemia. 

<ul class="summary-bullets"><li>SRPT’s Q1 revenue and earnings beat Wall Street expectations.&nbsp;</li><li>FDA-approved Elevidys came under scrutiny last year over concerns of acute liver failure and associated patient deaths.</li><li>Sarepta CEO Doug Ingram, however, struck an optimistic tone, saying that the company’s commercial portfolio has “begun to stabilize” and that Elevidys “is positioned to return to growth.”</li></ul> Shares of Sarepta Therapeutics Inc. (SRPT) fell 7% in after-hours trading on Wednesday after the company reported first-quarter 2026 results that beat Wall Street expectations on both revenue and earnings but highlighted ongoing softness in its flagship gene therapy Elevidys.The Cambridge-based biotech posted total revenue of $730.8 million, down 2% year-over-year but topping consensus estimates of roughly $475.01 million. Adjusted earnings per share for the three months ended March came in at $3.16, compared to a loss of $3.42 reported in the corresponding quarter of 2025, and comfortably above an analyst estimate of $1.09 in earnings per share.Net product revenue came in at $330.5 million, with Elevidys, Sarepta’s one-time gene therapy for Duchenne muscular dystrophy (DMD), generating $102 million in net product sales, down from the $375 million record in Q1 2025. The lowered Elevidys sales reflect the limitation of the drug’s addressable population to DMD patients who can walk following safety concerns flagged last year. &nbsp;Sarepta reiterated its full-year 2026 guidance for total net product revenue of $1.2 billion to $1.4 billion. Cash, cash equivalents, restricted cash and investments stood at $748.3 million at quarter-end.Sarepta CEO Doug Ingram, however, struck an optimistic tone, saying that the company’s commercial portfolio has “begun to stabilize” and that Elevidys “is positioned to return to growth.”FDA-approved Elevidys came under scrutiny last year over concerns of acute liver failure and associated patient deaths. While the company resumed shipments to patients who can walk after a temporary pause in shipments in July 2025, it is now working to address safety concerns in patients who cannot walk.The company is currently undertaking studies to develop a regimen that makes the therapy safe and usable in non-ambulatory patients by pretreating them with the immunosuppressant medication sirolimus before administering Elevidys. Sirolimus is commonly used to prevent organ rejection in kidney transplant patients.<h2 class="st-heading-2">How Did SRPT Retail Traders React?</h2>On Stocktwits, retail sentiment around SRPT stock jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours, while message volume increased from ‘normal’ to ‘high’ levels.A Stocktwits user opined that basic demand was never there for Elevidys.<stembedurl>https://www.stocktwits.com/LikesVikes/message/652520772</stembedurl>Another user dismissed the “short-term price reactions” and said they are going to hold on to the stock for a “long, long time.”<stembedurl>https://www.stocktwits.com/Dondetzela/message/652519939</stembedurl><a href="https://stocktwits.com/symbol/SRPT">SRPT stock</a> has fallen by about 51% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/spacexai-takes-off-elon-musk-consolidates-ai-empire-ahead-of-massive-ipo/cZQzjOQReOD">SpaceXAI Takes Off: Elon Musk Consolidates AI Empire Ahead Of Massive IPO</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Sarepta Therapeutics logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

SRPT Stock Plunges 7% After-Hours As Elevidys Demand Slumps — CEO Still Sees Return To Growth

The stock was weighed down after hours by lower sales reported for Sarepta’s gene therapy Elevidys. 

<ul class="summary-bullets"><li>The FDA Commissioner reportedly clarified that the FDA made no “corrupt sweetheart deals.”</li><li>Makary’s clarification comes on the heels of Health Secretary Robert F. Kennedy Jr. pinning the responsibility for the drug rejection on the FDA alone.</li><li>Replimune, for its part, said that it disagrees with the FDA about the sufficiency of the dataset it submitted while also accusing the agency of inconsistent communication and a slow-moving regulatory process.</li></ul> Shares of Replimune Group Inc (REPL) fell a steep 13% on Tuesday after U.S. Food and Drug Administration Commissioner Marty Makary backed the agency’s decision to refuse approval for the company’s experimental drug RP1.FDA refused to approve Replimune’s melanoma drug RP1 for the second time in April, citing insufficient data to provide “substantial evidence of effectiveness” in the treatment of unresectable advanced cutaneous melanoma.<h2 class="st-heading-2">Makary’s Defense</h2>“I don’t work for Replimune, I work for the American people, and I stand by the scientists at the FDA,” Makary reportedly said in an <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.cnbc.com/video/2026/05/05/watch-cnbcs-full-interview-with-fda-commissioner-marty-makary.html">interview</a> with CNBC’s David Faber.The FDA commissioner also added that three independent teams arrived at the same conclusion on the drug, while putting his weight behind his review teams. The agency did not make “corrupt sweetheart deals,” he said.“If your drug works, it’s going to get approved,” Makary said, while adding that the agency is not out to “smear any company.”Makary’s clarification comes on the heels of Health Secretary Robert F. Kennedy Jr. pinning the responsibility for the drug rejection on the FDA alone.Last month, the Health Secretary reportedly told a Senate hearing that he had little role in the FDA’s decision to reject RP1. "This decision comes out of FDA, and we trust ​the process there,” Kennedy reportedly said.<h2 class="st-heading-2">Medical Community Reacts</h2>Doctors, in an opinion <a href="https://stocktwits.com/news-articles/markets/equity/repl-ignites-on-doctor-fury-against-fda-melanoma-drug-snub-health-sec-steps-back/cZB9GvORebB">piece</a> published in The Wall Street Journal last month, criticized the FDA’s decision, noting that the initial panel that reviewed RP1 had recommended approval, which was later overruled by the then-FDA biologics chief, Vinay Prasad.The second team that reviewed the drug also did not say that the drug was ineffective, instead saying that it is “unclear whether the drug was effective,” the doctors said.“Denying patients a life-saving medicine for inexplicable reasons is the wrong kind of change. If Dr. Makary doesn’t understand that, the FDA needs a change in leadership,” the doctors said.<h2 class="st-heading-2">Replimune Alleges Inconsistency</h2>Replimune, for its part, said that it disagrees with the FDA about the sufficiency of the dataset it submitted while also accusing the agency of inconsistent communication and a slow-moving regulatory process.“A treatment desperately needed by patients will not be available. Not because the medicine failed. Because the system did,” Replimune CEO Sushil Patel said.<h2 class="st-heading-2">Replimune’s Efforts With RP1 Approval</h2>In late July 2025, the FDA issued a complete response letter regarding the company’s application for RP1 in combination with Nivolumab for the treatment of advanced melanoma.The agency said in the letter that it is unable to approve the application in its present form, and indicated that the trial conducted by the company for the drug is not considered to be an adequate and well-controlled clinical investigation that provides substantial evidence of effectiveness. It further urged that the company conduct and provide the results from a fresh trial for further consideration.Replimune subsequently resubmitted its application in October with additional information and analyses, but no additional trial.In April, the FDA said that the revised application does not alter its initial conclusion of the ineffectiveness of the trials conducted by the company.Replimune can either resubmit or withdraw its application within a year, the agency said.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around REPL stock stayed within the ‘bullish’ territory over the past 24 hours, while message volume stayed within ‘extremely low’ levels.A Stocktwits user said that the company is “done.”<stembedurl>https://www.stocktwits.com/mmr786/message/652309710</stembedurl>Another highlighted that the agency will not move on its decision for RP1.<stembedurl>https://www.stocktwits.com/Capitulation_0/message/652298850</stembedurl>A third user highlighted that the FDA commissioner does not seem “happy” with how REPL handled the rejection.<stembedurl>https://www.stocktwits.com/Dragonfire89/message/652298780</stembedurl><a href="https://stocktwits.com/symbol/REPL">REPL stock</a> is down 74% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/trump-china-xi-very-respectful-iran-war-not-challenged-by-china/cZQDPwdRe9j">Trump Says Xi Jinping Has Been Very Respectful About US Blockade On Iranian Oil Exports — 'We Haven't Been Challenged By China'</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Replimune logo is displayed on the screen of a smart tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

REPL Nosedives As FDA Chief Stands Firm Against Melanoma Treatment: ‘I Don’t Work For Replimune…’

FDA refused to approve Replimune’s melanoma drug RP1 for the second time in April, citing insufficient data to provide “substantial evidence of effectiveness” in the treatment of unresectable advanced cutaneous melanoma.

<ul class="summary-bullets"><li>In Mirum’s trial, volixibat delivered statistically significant and clinically meaningful reductions in cholestatic pruritus or an intense, often debilitating itching caused by liver diseases.&nbsp;</li><li>The company added that it now expects topline data from a separate study of volixibat in primary biliary cholangitis in the first quarter of 2027.</li></ul> Shares of Mirum Pharmaceuticals, Inc. (MIRM) closed 10% higher on Monday, marking its best day since mid-December, after the company said that its investigational drug volixibat met the primary endpoint in a mid-stage study in patients with a rare liver disease.Primary Sclerosing Cholangitis (PSC) is a chronic, progressive, and rare liver disease characterized by inflammation, scarring, and narrowing of the bile ducts. In Mirum’s trial, volixibat delivered statistically significant and clinically meaningful reductions in cholestatic pruritus or an intense, often debilitating itching caused by liver diseases.In the primary analysis cohort of 111 patients with moderate-to-severe itch at baseline, volixibat 20 mg twice daily produced a 2.72-point improvement from baseline on a standardized scale, compared with a 1.08-point improvement for placebo, the company said. Statistically significant itch relief was observed as early as two weeks after starting therapy and was also seen in the secondary cohort of patients with mild itch, it added.Severe adverse events associated with the drug in the trial consisted mainly of gastrointestinal side effects and elevations in liver laboratory values such as ALT and bilirubin, the company said.<h2 class="st-heading-2">FDA Approval And Process</h2>The results position volixibat as a potential approved therapy for the severe itching that is one of the most burdensome symptoms of PSC, a rare and progressive liver disease with no approved treatments, according to Mirum’s chief medical officer Joanne Quan.Mirum said it has scheduled a pre-New Drug Application meeting with the U.S. Food and Drug Administration for this summer and plans to submit an NDA in the second half of 2026. The company added that it now expects topline data from a separate study of volixibat in primary biliary cholangitis in the first quarter of 2027.<h2 class="st-heading-2">How Did MIRM Retail Traders React?</h2>On Stocktwits, retail sentiment around MIRM jumped from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘extremely high’ levels.A Stocktwits user voiced optimism for a buyout at up $160/share price.<stembedurl>https://www.stocktwits.com/BZAJDEL/message/652215094</stembedurl><a href="https://stocktwits.com/symbol/MIRM">MIRM stock </a>has gained about 140% over the past 12 months.Read More: <a href="https://stocktwits.com/news-articles/markets/equity/ford-warns-of-no-fair-fight-with-chinese-evs-while-byd-dwarfs-its-april-output/cZQu5XdReJq">Ford Warns Of ‘No Fair Fight’ With Chinese EVs While BYD Dwarfs Its April Output</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Mirum Pharmaceuticals logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

MIRM Stock Clocks Best Day In 4.5 Months On Liver Disease Trial Data: Retail Eyes Buyout At A Premium

Mirum said it has scheduled a pre-New Drug Application meeting with the U.S. Food and Drug Administration for this summer to discuss its drug volixibat in the treatment of Primary Sclerosing Cholangitis. 

<ul class="summary-bullets"><li>H.C. Wainwright upgraded Celcuity to ‘Buy’ from ‘Neutral’ and raised its price target to $165 from $94, citing positive Phase 3 trial results.</li><li>Citizens raised its price target for Celcuity to $160 from $150 and maintained an ‘Outperform’ rating.</li><li>The firm highlighted expected progression-free survival of 11–12 months for the triplet regimen and stronger-than-anticipated efficacy from the doublet versus control.</li></ul>Celcuity Inc. (CELC) could become an acquisition target in the oncology space, according to analysts, after the company reported positive results in the Phase 3 trial of its breast cancer therapy.According to TheFly, analysts at HC Wainwright expressed optimism about the company’s prospects after Celcuity’s breast cancer therapy, gedatolisib, achieved its primary endpoint in a Phase 3 trial.<a href="https://stocktwits.com/symbol/CELC">Celcuity shares</a> were up more than 15% in Monday’s pre-market trade, extending the gains from Friday. If CELC stock ends Monday’s regular trading session with these gains, it would be the stock’s best single-day gain in more than six months.Retail sentiment on Stocktwits around the company trended in the ‘extremely bullish’ territory, with message volumes at ‘extremely high’ levels at the time of writing.<h2 class="st-heading-2">Why Are Analysts Optimistic?</h2>Analysts at H.C. Wainwright upgraded Celcuity to ‘Buy’ from ‘Neutral’ and raised their price target to $165 from $94, citing positive Phase 3 trial results. The firm said gedatolisib has the potential to be a “game-changing” treatment for HR+/HER2- advanced breast cancer and could position Celcuity as an acquisition target.Citizens raised its price target for Celcuity to $160 from $150 and maintained an ‘Outperform’ rating. The firm said the data suggest the drug could expand its use in second-line ER+/HER2- advanced breast cancer, demonstrating benefit regardless of PI3K mutation status.It also pointed to expected progression-free survival of 11–12 months for the triplet regimen and stronger-than-anticipated efficacy from the doublet versus control.Stifel analyst Stephen Willey raised the firm’s price target on Celcuity to $150 from $125 and maintained a ‘Buy’ rating. Willey said the “statistically significant and clinically meaningful” improvement in the Phase 3 trial was largely expected, but noted that its selection as a late-breaking oral presentation at the ASCO Annual Meeting on June 2 was the bigger surprise.<h2 class="st-heading-2">Celcuity’s Latest Announcement</h2>Celcuity reported positive Phase 3 results for gedatolisib plus fulvestrant, with or without palbociclib, in patients with HR+/HER2- advanced breast cancer after prior CDK4/6 and aromatase inhibitor treatment.The company stated that the gedatolisib triplet regimen met the primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival compared with alpelisib plus fulvestrant.The gedatolisib doublet also delivered a statistically significant PFS benefit compared with the control arm, despite being a secondary endpoint; both regimens demonstrated manageable safety profiles with no new safety concerns.HR+/HER2- breast cancer is the most common form of the disease, representing about 70% of all cases. Within this group, roughly 40% of patients carry PIK3CA mutations.<a href="https://stocktwits.com/symbol/CELC">CELC stock</a> is up 26% year-to-date and 1,063% over the past 12 months. The Tema Oncology ETF (CANC) is up 50% over the past 12 months, while the S&amp;P Biotech ETF (XBI) is up 58%.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/gamestop-ryan-cohen-ebay-build-larger-business-gme-ebay-stock/cZQMpRjReJc">GameStop's Ryan Cohen Says He Plans On Bringing An Entrepreneurial Mindset To eBay And Building Something 'Much Larger'</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Celcuity logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Wall Street Believes Celcuity Could Become An Acquisition Target – Why This Analyst Raised Their Price Target By A Whopping 76%

H.C. Wainwright expressed optimism about the company’s prospects after Celcuity’s breast cancer therapy achieved its primary endpoint in a Phase 3 trial.

<ul class="summary-bullets"><li>The open-label study evaluated Celcuity’s investigational gedatolisib in combination with fulvestrant, both with and without palbociclib.</li><li>Celcuity plans to submit the results to the FDA as part of a supplemental New Drug Application and to other regulators thereafter.</li><li>Celcuity has submitted an application already for gedatolisib in patients with some types of breast cancer, on which the agency will decide on July 17.&nbsp;</li></ul>Shares of Celcuity Inc. (CELC) jumped 14% after hours after the company said on Friday that its experimental cancer drug delivered a statistically significant and clinically meaningful improvement in progression-free survival (PFS) in patients with certain advanced breast cancers.The open-label study evaluated Celcuity’s investigational gedatolisib in combination with fulvestrant, both with and without palbociclib. Patients had progressed after prior treatment with a palbociclib plus an aromatase inhibitor.Both the gedatolisib triplet and doublet regimens outperformed the control arm, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival.Both gedatolisib regimens were generally well tolerated with manageable safety profiles, the company said. Detailed data will be presented on June 2 at the ASCO Annual Meeting in Chicago.“These positive topline results demonstrate the potential for gedatolisib to become a transformative new medicine for the treatment of patients with PIK3CA-mutant HR+/HER2- advanced breast cancer,” said Igor Gorbatchevsky, Celcuity’s chief medical officer.Celcuity plans to submit the results to the FDA as part of a supplemental New Drug Application and to other regulators thereafter.Celcuity has submitted an application already for gedatolisib in patients with some types of breast cancer, on which the agency will decide on July 17. The agency also granted priority review to the drug in the indication.<h2 class="st-heading-2">How Did CELC Retail Traders React?</h2>On Stocktwits, retail sentiment stayed within the ‘bearish’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.A Stocktwits user applauded the trial data.<stembedurl>https://www.stocktwits.com/CharlieeMungerTWITS/message/652069628</stembedurl><a href="https://stocktwits.com/symbol/CELC">CELC stock</a> has rallied over 1000% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/vnda-stock-rises-after-hours-on-commercial-launch-of-motion-sickness-drug/cZQVZvNReet">VNDA Stock Rises After Hours On Commercial Launch Of Motion Sickness Drug</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

CELC Stock Jumps After Hours On Positive Breast Cancer Trial Data

The company said that its experimental cancer drug delivered a statistically significant and clinically meaningful improvement in progression-free survival (PFS) in patients with certain advanced breast cancers.

<ul class="summary-bullets"><li>The drug offers simple dosing with just one or two capsules a day taken approximately an hour before travel.</li><li>Patients can access Nereus at a cash-pay price of just $85 per dose, a meaningful discount from the standard list price of $255 per dose, the company said.</li><li>Vanda is also studying the drug in gatroparesis and the prevention of nausea and vomiting induced by GLP-1 drugs popularly used for weight loss and diabetes.</li></ul> Shares of Vanda Pharmaceuticals Inc. (VNDA) jumped 4% after hours on Friday after the company announced that its motion sickness drug is now commercially available across the U.S.The U.S. Food and Drug Administration approved Nereus for the prevention of vomiting induced by motion in adults in December. The FDA approval marked the first new pharmacologic treatment for motion sickness in more than 40 years.<h2 class="st-heading-2">Clinical Data For Nereus</h2>According to Vanda, motion sickness affects roughly 25 to 30% of adults during everyday travel by car, plane, or boat. Patients can now access the drug from the company’s dedicated direct-to-consumer portal for the drug or from retail pharmacies with a prescription. Patients can access Nereus at a cash-pay price of just $85 per dose, a meaningful discount from the standard list price of $255 per dose, the company said.The FDA approved Nereus following two late-stage trials conducted under real-world conditions on the open sea. In both trials, Nereus significantly prevented vomiting compared to placebo, confirming the drug's effectiveness. The drug offers simple dosing with just one or two capsules a day taken approximately an hour before travel.Vandas is also studying the drug in gatroparesis and the prevention of nausea and vomiting induced by GLP-1 drugs popularly used for weight loss and diabetes.<h2 class="st-heading-2">How Did VNDA Retail Traders React?</h2>On Stocktwits, retail sentiment around VNDA stock fell from ‘neutral’ to ‘bearish’ territory over the past 24 hours while message volume remained at ‘normal’ levels.A Stocktwits user opined that the company could be bought out by GLP-1 drug makers like Eli Lilly, Novo Nordisk, or Pfizer in light of its efforts in treating the side effects of those drugs.<stembedurl>https://www.stocktwits.com/hktrader12/message/652070630</stembedurl><a href="https://stocktwits.com/symbol/VNDA">VNDA stock</a> has gained 58% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/nspr-rallies-after-hours-on-fda-green-light-for-key-stroke-prevention-trial/cZQVklHReeA">NSPR Rallies After Hours On FDA Green Light for Key Stroke-Prevention Trial Despite Withdrawn Annual Guidance</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

The Vanda Pharmaceuticals Inc. logo is pictured before a regular season Major League Baseball game between the Chicago White Sox and the Detroit Tigers on September 05, 2025. (Photo by Joseph Weiser/Icon Sportswire via Getty Images)

VNDA Stock Rises After Hours On Commercial Launch Of Motion Sickness Drug

The U.S. Food and Drug Administration approved Nereus for the prevention of vomiting induced by motion in adults in December.

<ul class="summary-bullets"><li>Summit on Thursday reported a first-quarter 2026 net loss of $189.4 million, more than triple the $62.9 million loss a year earlier.</li><li>Piper Sandler lowered its price target on Summit to $16 from $17 and maintained a ‘Neutral’ rating on the shares.</li><li>The company’s interim update from its HARMONi-3 trial disappointed investors.&nbsp; Final data from the cohort remain on track for the second half of 2026.</li></ul> Shares of Summit Therapeutics Inc. (SMMT) closed 25% lower on Friday after the company reported a wider loss for the first quarter and an interim analysis update from its HARMONi-3 trial, prompting Piper Sandler to lower its price target on the stock.Piper Sandler lowered its price target on Summit to $16 from $17 and maintained a ‘Neutral’ rating on the shares.<h2 class="st-heading-2">Summit’s Q1 Earnings</h2>Summit on Thursday reported a first-quarter 2026 net loss of $189.4 million, more than triple the $62.9 million loss a year earlier, as the company ramps up spending on its lead asset ivonescimab in the treatment of non-small cell lung cancer (NSCLC).The company is studying Ivonescimab combined with chemotherapy in patients with first-line metastatic NSCLC in its HARMONi-3 trial, with two distinct cohorts to be analyzed separately for squamous tumors and non-squamous tumors.In squamous tumors, an independent Data Monitoring Committee completed a pre-specified interim progression-free survival analysis in Q2 2026 and recommended that the study continue as planned with no safety concerns, the company said. However, it did not hit the high statistical bar for early success/stop. Final data from the cohort remain on track for the second half of 2026.In the non-squamous tumors cohort, enrollment is expected to be completed by the end of Q2 2026, and data readout is targeted for the first half of 2027.According to Piper Sandler, investors are now questioning whether the impressive effect size seen in Akeso's HARMONi-6 can be replicated in Summit's global HARMONi-3.HARMONi-6 is a trial conducted in China and sponsored by Akeso, which evaluates ivonescimab in combination with platinum-based chemotherapy compared with the drug tislelizumab and platinum-based chemotherapy in non-small cell lung cancer.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around SMMT stock rose from ‘bearish’ to ‘bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘high’ levels.A Stocktwits user dismissed the selloff as an overreaction.<stembedurl>https://www.stocktwits.com/northern18738901/message/652058452</stembedurl>Another echoed the sentiment, expressing optimism for the stock to rally back up over $18 in two weeks.<stembedurl>https://www.stocktwits.com/BobBijawklah/message/652053579</stembedurl><a href="https://stocktwits.com/symbol/SMMT">SMMT stock</a> has fallen 35% over the past 12 months.Read More: <a href="https://stocktwits.com/news-articles/markets/equity/nspr-rallies-after-hours-on-fda-green-light-for-key-stroke-prevention-trial/cZQVklHReeA">NSPR Rallies After Hours On FDA Green Light for Key Stroke-Prevention Trial Despite Withdrawn Annual Guidance</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Summit Therapeutics company logo is seen on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

SMMT Stock Plunges On Wider Q1 Loss, Lung Cancer Clinical Trial Update

Summit on Thursday reported a first-quarter 2026 net loss of $189.4 million, more than triple the $62.9 million loss a year earlier.

<ul class="summary-bullets"><li>While durable responses were observed in select patients through extended follow-up, the overall magnitude and consistency of activity were not sufficient to support continued development relative to other pipeline programs, it said.&nbsp;</li><li>However, the experimental therapy demonstrated a differentiated tolerability profile with fewer gastrointestinal, dermatologic, and subcutaneous adverse events as compared to other drugs belonging to its category.&nbsp;</li><li>The company also clarified that the decision to discontinue JANX008 is program-specific and part of its efforts to prioritize parts of its portfolio.</li></ul>Shares of Janux Therapeutics, Inc. (JANX) edged up 1% after hours after the company said on Monday that it will discontinue development of its experimental program called JANX008 to focus its resources on its remaining pipeline.The company said that it came to the decision after completing early-stage trials across multiple solid tumor indications and an internal review of the data. While durable responses were observed in select patients through extended follow-up, the overall magnitude and consistency of activity were not sufficient to support continued development relative to other pipeline programs, it said.However, the experimental therapy demonstrated a differentiated tolerability profile with fewer gastrointestinal, dermatologic, and subcutaneous adverse events as compared to other drugs belonging to its category, the company said. Overall safety profile also allows for outpatient dosing, the company noted.The company also clarified that the decision to discontinue JANX008 is program-specific and part of its efforts to prioritize parts of its portfolio.“Our decision to discontinue JANX008 reflects the disciplined approach we take to advancing our pipeline,” said David Campbell, Ph.D., President and Chief Executive Officer of Janux. “We evaluate each program against a high bar for safety, activity, and differentiated profile. We prioritize resources toward programs that meet these criteria and offer opportunities to deliver best-in-class outcomes.”Janux is currently also evaluating other experimental drugs for the treatment of prostate cancer as well as autoimmune diseases. Earlier this month, the company said that it dosed the first participant in an early-stage study of JANX014, one of its candidates for prostate cancer.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around JANX fell from ‘neutral’ to ‘bearish’ territory over the past 24 hours, while message volume remained at ‘high’ levels.JANX stock has fallen 53% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/crmd-stock-jumps-as-antifungal-drug-clears-key-trial-for-2-billion-preventive-market/cZBNx6bRePY">CRMD Stock Jumps As Antifungal Drug Clears Key Trial For $2B Preventive Market</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a Janux Therapeutics company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

JANX Stock Edges Up After Hours After Discontinuing Cancer Program In Favor Of Remaining Pipeline

The company said that it came to the decision after completing early-stage trials across multiple solid tumor indications and an internal review of the data.

SPDR Series Trust - State Street SPDR S&P Biotech ETF

Buying for a long-term investment

Buying for a short-term trade

Trading around the volatility

Avoiding it 

Cerebras ($CRBS) IPO day is Thursday, how are you playing it?  
 
Drop a comment with your strategy.

XBI
SPDR S&P Biotech ETF

Feed

News

Sentiment

Fundamentals

Info

Historical Earnings

Latest XBI News

XBISPDR S&P Biotech ETF